Results 121 to 130 of about 765,112 (149)

Small molecule tyrosine kinase inhibitors in pancreatic cancer

open access: yes, 2008
Sachin Gupta, Bassel F El-RayesDepartment of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USAAbstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for ...
Sachin Gupta, Bassel F El-Rayes
core  

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

open access: yesHaematologica, 2022
Jonathan J. Pinney   +11 more
doaj   +1 more source

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

open access: yesHaematologica, 2019
Chiara Tarantelli   +11 more
doaj   +1 more source

SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA

open access: yesHaematologica, 2019
Subbaiah Chary Nimmagadda   +7 more
doaj   +1 more source

The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation

open access: yesHaematologica, 2017
Nicole Stadler   +10 more
doaj   +1 more source

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

open access: yesHaematologica, 2019
Toby A. Eyre   +11 more
doaj   +1 more source

Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment

open access: yeseJHaem
Takafumi Tsushima   +12 more
doaj   +1 more source

Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors

New England Journal of Medicine, 2022
Mark Geyer, Kevin T Ebata, Eric Wang
exaly  

Home - About - Disclaimer - Privacy